The fact
Genfit prepares a rapid graphical presentation of its challenges, while Abivax announces the presentation of obefazimod ahead of imminent approval.
These moves reflect the volatility of the French biotech sector, where major clinical milestones structure share prices.
Click the link to read an article on the topic: